Top Research Reports for Merck, ServiceNow & Blackstone

20.02.24 21:11 Uhr

Werte in diesem Artikel
Aktien

117,32 EUR 0,18 EUR 0,15%

118,20 EUR 1,00 EUR 0,85%

153,80 EUR 1,65 EUR 1,08%

720,20 EUR 0,30 EUR 0,04%

Indizes

PKT PKT

PKT PKT

1.547,7 PKT -4,0 PKT -0,26%

17.930,3 PKT -24,2 PKT -0,13%

7.057,4 PKT -9,5 PKT -0,13%

2.975,3 PKT 0,8 PKT 0,03%

2.143,9 PKT 0,6 PKT 0,03%

192,8 PKT -0,4 PKT -0,18%

37.983,2 PKT -475,8 PKT -1,24%

509,3 PKT -0,7 PKT -0,14%

9.576,4 PKT -16,4 PKT -0,17%

17.815,0 PKT -42,0 PKT -0,24%

17.890,4 PKT -113,9 PKT -0,63%

15.190,1 PKT -45,4 PKT -0,30%

7.076,2 PKT -14,3 PKT -0,20%

16.603,7 PKT -28,7 PKT -0,17%

2.432,8 PKT -34,9 PKT -1,42%

5.123,4 PKT -75,7 PKT -1,46%

17.862,6 PKT -184,3 PKT -1,02%

Tuesday, February 20, 2024The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), ServiceNow, Inc. (NOW) and Blackstone Inc. (BX). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>Merck shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past six months (+18.2% vs. +13.7%) reflecting favorable demand momentum for products like Keytruda and Gardasil. With continued label expansion into new indications, particularly earlier-stage launches, Keytruda is expected to see continued growth.Animal health and vaccine products are core growth drivers. Merck boasts a strong cancer pipeline, including Keytruda, which should drive long-term growth. Merck is investing in M&A activity to strengthen its pipeline.However, generic competition for several drugs and rising competitive pressure, mainly on the diabetes franchise, will continue to be overhangs on the top line. There are concerns about Merck’s ability to grow its non-oncology business ahead of Keytruda’s loss of exclusivity later in the decade.(You can read the full research report on Merck here >>>)Shares of ServiceNow have outperformed the Zacks Computers - IT Services industry over the past six months (+37.9% vs. +30.9%). The company has been benefiting from the rising adoption of its workflows by enterprises undergoing digital transformation. It had 1897 total customers with more than $1 million in annual contract value at the end of the fourth quarter.ServiceNow has been benefiting from the rising adoption of its workflows by enterprises undergoing digital transformation. Security and risk had a terrific quarter with 12 of the top 20 deals, out of which nine deals were more than $1 million. Customer, Employee and Creator workflows each had double-digit deals over $1 million.It is benefiting from strong demand for its generative AI-powered solutions with the launch of Vancouver. Nevertheless, ServiceNow is suffering from high inflation, stiff competition, and challenging macro-economic environment.(You can read the full research report on ServiceNow here >>>)Blackstone shares have outperformed the Zacks Financial - Miscellaneous Services industry over the past six months (+31.6% vs. +17.7%). The company’s strong revenue mix, global footprint and solid assets under management (AUM) balance are expected to keep aiding its financials. Its robust fund-raising ability will support top-line growth.Yet, elevated consolidated expenses are likely to hamper Blackstone’s bottom-line growth in the near term. Also, lower chances of sustainability of the company's capital distribution activities are worrisome. The company has been facing substantial outflows in some of its funds of late, which are likely to hurt its financials.(You can read the full research report on Blackstone here >>>)Other noteworthy reports we are featuring today include Marsh & McLennan Companies, Inc. (MMC), Gilead Sciences, Inc. (GILD) and Diageo plc (DEO).Director of ResearchSheraz MianNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>Today's Must ReadKeytruda to Remain Merck's (MRK) Key Top-Line DriverGrowing Customer Base & Partnerships Aid ServiceNow (NOW)Fund-Raising Ability Aids Blackstone (BX), High Costs AilsFeatured ReportsRising Revenues Aid Marsh & McLennan (MMC) Amid High CostsDiverse product offerings & solid client retention will boost Marsh & McLennan's top line, as per the Zacks analyst. However, increasing expenses are likely to hamper margins.Biktarvy, Oncology Fuel Gilead (GILD) Amid Pipeline SetbacksPer the Zacks analyst, strong performance from flagship HIV therapy Biktarvy and contribution from the oncology franchise boost Gilead. However, the recent pipeline setbacks weigh on shares.Productivity Initiatives to Aid Diageo (DEO) Amid InflationPer the Zacks analyst, Diageo is on track with its commitment to deliver $2 billion of productivity savings over the next three years. Productivity cost savings aided margins in 1H24.Robust Public Sector Demand Aids Vulcan (VMC), High Cost AilPer the Zacks Analyst, Vulcan is benefiting from robust public sector demand and pricing growth. However, low residential demand and uncertain energy costs are a concern.Overseas Growth Aids DaVita (DVA) Amid Stiff CompetitionThe Zacks analyst is upbeat about DaVita's steady expansion in the international markets via acquisitions of dialysis centers despite its operation in a highly competitive market.Iridium's (IRDM) Performance Gains from Higher SubscribersPer the Zacks analyst, Iridium's performance is gaining from increasing subscribers. The company expects engineering and support revenue to benefit owing to the space development agency contractAllegiant's (ALGT) Fleet-Upgrade Efforts Aid, Costs AilPer the Zacks analyst, Allegiant Travel's fleet modernization program is praiseworthy. High labor costs are, however, hurting the bottom line.New UpgradesHonda (HMC) Set to Ride on Cost Containment Initiatives The Zacks analyst is optimistic about Honda's efforts to control costs and optimize production capacity, thereby generating savings that can be directed toward more profitable opportunities.Strong Clientele & Bookings Aids GoDaddy's (GDDY) ProspectsPer the Zacks analyst, GoDaddy benefits from strong bookings primarily driven by strong customer additions and price increases in various domains. Rising Money Market Assets Aid Federated's (FHI) AUM GrowthPer the Zacks analyst, the continued strategic acquisition of money market assets will aid Federated's AUM growth. Manageable debt levels and sustainable capital distributions are other positives.New DowngradesStiff Competition and Regulations Ail Devon Energy (DVN)Per the Zacks analyst, Devon (DVN) results likely to be impacted by competition it faces to secure drilling rights and acquire properties. New regulations can increase cost and lower profitability.Nabors (NBR) Weighed Down by Massive Debt Burden The Zacks analyst believes that Nabors Industries' high debt-to-capitalization of 82% is a concern, as it restricts the company's financial freedom to tap into growth opportunities.Cenovus (CVE) to Suffer From Halting Crude Price HedgingPer the Zacks analyst, Cenovus' decision to cease crude price hedging leaves it more vulnerable to crude price declines than competitors with hedge protection.Just Released: Zacks Top 10 Stocks for 2024Hurry – you can still get in early on our 10 top tickers for 2024. Hand-picked by Zacks Director of Research, Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2024. You can still be among the first to see these just-released stocks with enormous potential.See New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Blackstone Inc. (BX): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Marsh & McLennan Companies, Inc. (MMC): Free Stock Analysis Report Diageo plc (DEO): Free Stock Analysis Report ServiceNow, Inc. (NOW): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Blackstone

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Blackstone

NameHebelKOEmittent
NameHebelKOEmittent
Werbung

Quelle: Zacks

Nachrichten zu Merck KGaA

Analysen zu Merck KGaA

DatumRatingAnalyst
26.03.2024Merck BuyJefferies & Company Inc.
26.03.2024Merck BuyUBS AG
20.03.2024Merck KaufenDZ BANK
18.03.2024Merck OverweightJP Morgan Chase & Co.
12.03.2024Merck OverweightBarclays Capital
DatumRatingAnalyst
26.03.2024Merck BuyJefferies & Company Inc.
26.03.2024Merck BuyUBS AG
20.03.2024Merck KaufenDZ BANK
18.03.2024Merck OverweightJP Morgan Chase & Co.
12.03.2024Merck OverweightBarclays Capital
DatumRatingAnalyst
06.12.2023Merck HaltenDZ BANK
27.11.2023Merck HaltenDZ BANK
27.04.2023Merck HaltenDZ BANK
10.11.2022Merck NeutralUBS AG
05.08.2022Merck HoldJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
DatumRatingAnalyst
06.03.2023Merck VerkaufenDZ BANK
02.03.2023Merck SellGoldman Sachs Group Inc.
07.02.2023Merck SellGoldman Sachs Group Inc.
02.02.2023Merck VerkaufenDZ BANK
15.11.2022Merck SellGoldman Sachs Group Inc.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Merck KGaA nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"